

End Brain Cancer Initiative Looking to Partner with GBM Drug Development Companies to Help Fight for Patient Access

EBCI will be on-site at the 5th Annual Glioblastoma Drug Development Summit March 26th to March 28th in Boston, MA.

REDMOND, WASHINGTON, UNITED STATES, March 25, 2024

/EINPresswire.com/ -- The End Brain Cancer Initiative (EBCI) engages directly with drug development companies to insert the patient voice into trial protocols and patient disease education and awareness campaigns. As part of this mission, we will be on-site at the 5th Annual Glioblastoma Drug Development Summit March 26th to March 28th in Boston, MA.



Shawn Drennan, EBCI Treasurer & Board Member

Shawn Drennan, EBCI Treasurer & Head of Finance & Operations, will be on-site to meet with drug development companies that want to partner with EBCI on patient disease education and clinical trial programs & services. Click the link to view Shawn's calendar and set a meeting with her for Tuesday 3/26, Wednesday 3/27, or Thursday 3/28 (Eastern Time) at the EBCI Booth: <https://calendly.com/shawn-15jf/gbm-drug-dev-summit>

“

We are grateful to be at the GBM Drug Development Table and part of the conversation to increase patient education and access.”

Dellann Elliott Mydland

“We are grateful to be at the GBM Drug Development Table and part of the conversation to increase patient education and access,” said Dellann Elliott Mydland, EBCI President & CEO. The 5th Annual Glioblastoma Drug Development

Summit is sponsored by The End Brain Cancer Initiative, Novocure, FYR, Kiyatec, Renishaw, and Sutter Health.

The End Brain Cancer Initiative is a 501(c)3 non-profit patient organization focused on disease education, awareness, outreach and increasing patient access. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund, is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with medical teams. Learn more about and support the End Brain Cancer Initiative's work and mission at EndBrainCancer.org.

Dellann Elliott Mydland
End brain cancer Initiative
+1 425-444-2215

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/698622085>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.